Analyze biopharma M&A and licensing deals using SEC EDGAR, web search, and CT.gov data.
npx skills add https://github.com/DrMoony/PharmaNova --skill deal-scanner
Please help me install this Agent Skill. Skill: deal-scanner Source: https://github.com/DrMoony/PharmaNova/tree/main/.claude/skills/deal-scanner Command: npx skills add https://github.com/DrMoony/PharmaNova --skill deal-scanner
This Skill provides a comprehensive analysis of Biopharma M&A/Licensing deals, offering comparables, valuation, and strategic insights.
Activate the deal-scanner skill and provide keywords like 'deal', 'M&A', 'licensing', or 'acquisition' to begin the analysis.
High-intent search queries and answers about installing and using this skill.
Biopharma M&A and licensing deal analysis extracts SEC EDGAR filings, web data, and CT.gov records to perform comparables analysis, deal valuation, and strategic interpretation. It benchmarks phase-specific metrics to provide comprehensive strategic insights.
Yes, biopharma licensing deal valuation provides phase-specific benchmarks for comparative analysis. It extracts clinical trial data from CT.gov and financial records to evaluate deal comparables across different development stages.
The best way to value biopharma acquisitions uses SEC EDGAR data parsing combined with statistical analysis and web crawling. This approach generates deal comparables and strategic insights by extracting and comparing historical transaction structures.
Yes, comprehensive biopharma M&A comparables require web crawling, data parsing, and statistical analysis capabilities. The workflow collects data from web searches, SEC EDGAR, and CT.gov to ensure accurate comparative analysis and valuation.
Generating strategic insights for biopharma M&A transactions involves breaking down the workflow into data collection, comparables analysis, valuation, and strategic interpretation. This structured process yields actionable reporting from extracted SEC and clinical data.
Yes, the edgartools dependency is required to parse SEC EDGAR filings for biopharma deal analysis. It enables the data extraction and web crawling capabilities necessary to retrieve financial records for comparables and valuation.
rebyteai-templateAnalyze SEC EDGAR filings for financial statements and insider trading data.
Snowflake-LabsAnalyze investment deal pipelines with credit metrics and market comparables.
yennanliuAnalyze SEC Form 4 filings to report insider sentiment and significant transactions.
alirezarezvaniAnalyze strategic positions and model financial scenarios for CEO decisions.
